Javascript must be enabled to continue!
A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data
View through CrossRef
Abstract
The main objective of this study was to validate an algorithm and experimental setup to simulate first-order absorption pharmacokinetic profiles without altering the standard
in vitro
hollow fiber infection model (HFIM). For that, clinical cerebrospinal fluid (CSF) linezolid concentrations after 30-minute infusions at dosing regimens 600 mg q12 h, 900 mg q12 h, and 900 mg q8 h were reproduced in the HFIM over 4 days.
To approximate the apparent first-order absorption observed on CSF pharmacokinetic profiles, we split the dosing interval into a series of sub-intervals during which continuous infusions were delivered to the system. During each sub-interval, the same amount of linezolid was delivered but the sub-intervals had different durations and flow rates which were computed by a newly developed algorithm.
In addition, we independently reproduced plasma concentrations to validate our system.
Samples were collected from the central reservoir and the extracapillary space (ECS) of the cartridge of the HFIM and assayed by liquid chromatography-tandem mass spectrometry. Observed pharmacokinetic parameters and concentrations in the ECS were compared with the target clinical pharmacokinetic parameters and concentrations.
Observed pharmacokinetic parameters were within 20 % of target pharmacokinetic parameters for all experiments, thus validating the ability of our experimental setup to reproduce plasma and CSF linezolid pharmacokinetic profiles.
The algorithm and setup are available in the open-source web application
https://varacli.shinyapps.io/hollow_fiber_app/
to easily design other HFIM experiments.
Title: A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data
Description:
Abstract
The main objective of this study was to validate an algorithm and experimental setup to simulate first-order absorption pharmacokinetic profiles without altering the standard
in vitro
hollow fiber infection model (HFIM).
For that, clinical cerebrospinal fluid (CSF) linezolid concentrations after 30-minute infusions at dosing regimens 600 mg q12 h, 900 mg q12 h, and 900 mg q8 h were reproduced in the HFIM over 4 days.
To approximate the apparent first-order absorption observed on CSF pharmacokinetic profiles, we split the dosing interval into a series of sub-intervals during which continuous infusions were delivered to the system.
During each sub-interval, the same amount of linezolid was delivered but the sub-intervals had different durations and flow rates which were computed by a newly developed algorithm.
In addition, we independently reproduced plasma concentrations to validate our system.
Samples were collected from the central reservoir and the extracapillary space (ECS) of the cartridge of the HFIM and assayed by liquid chromatography-tandem mass spectrometry.
Observed pharmacokinetic parameters and concentrations in the ECS were compared with the target clinical pharmacokinetic parameters and concentrations.
Observed pharmacokinetic parameters were within 20 % of target pharmacokinetic parameters for all experiments, thus validating the ability of our experimental setup to reproduce plasma and CSF linezolid pharmacokinetic profiles.
The algorithm and setup are available in the open-source web application
https://varacli.
shinyapps.
io/hollow_fiber_app/
to easily design other HFIM experiments.
Related Results
Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy
Efficacy and Safety of Linezolid in Immunocompromised Patients with Hematological Malignancy
Abstract
Abstract 4838
BACKGROUND:
The aim of this study was to determine the safety, tolerance and efficacy of l...
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
P-1977. Adverse Event Profile of Vancomycin vs. Linezolid in Real-World Reports: A Disproportionality Analysis from the AERS Database
Abstract
Background
Vancomycin and linezolid are critical agents in the treatment of multidrug-resistant gram-positive in...
Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients
Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients
Abstract
Linezolid is a widely used antimicrobial agent in clinical practice; however, its usage is often limited by linezolid‐induced thromb...
Raman probe based on hollow-core microstructured fiber
Raman probe based on hollow-core microstructured fiber
Surface-enhanced Raman scattering (SERS) technology can effectively enhance the Raman signal of sample molecules. It has a higher sensitivity to detect biomolecule and thus has man...
Anopheles gambiae Larval Development and Toxicity’s Reduction of Conventional Agriculture Insecticides in the Laboratory Conditions
Anopheles gambiae Larval Development and Toxicity’s Reduction of Conventional Agriculture Insecticides in the Laboratory Conditions
Background: Vector control of Malaria is mainly made by using impregnated bed nets and insecticides pulverizations indoor or/and outdoor. Besides, appearance and development of res...
Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future
Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future
Abstract
Background: Linezolid has been increasingly used in tertiary NICUs. The objectives of this study were to explore the indications of these linezolid prescriptions, ...
Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future
Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future
Abstract
Background
Linezolid has been increasingly used in tertiary NICUs. The objectives of this study were to explore the indications of these linezolid prescriptions, ...
Stability indicating HPLC method development and validation for quantification of Linezolid oral suspension dosage forms
Stability indicating HPLC method development and validation for quantification of Linezolid oral suspension dosage forms
Abstract
Linezolid is a synthetic oxazolidinone antimicrobial agent with activity against gram-positive bacteria. The development of a reliable, sensitive, and specific HPL...

